What is IBRX's current stock price?

As of now, IBRX is trading at $1.98, with a daily change of -2.94%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

IBRX Stock Analysis & IQ Rating | ImmunityBio

IBRX

ImmunityBio

$1.98

-$0.06 | -2.94%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$4.27

MKT CAP

$1.95B

52W Low

$1.83

VOL

$10.92M

P/E Ratio

N/A

AVG VOL

$12.99M

RSI

41.10

TREND

Downtrend

BQ Stock IQ

Login to see ImmunityBio (IBRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

IBRX Target Price

Login to display

Strengths

IBRX Rewards

Upgraded on attractively valued

IBRX Rewards

Investors confidence is positive

IBRX Price Performance

$2.2 (-10.00%)

$2.53 (-21.74%)

$2.44 (-18.85%)

$3.04 (-34.87%)

1year

6month

3month

1month

IBRX Risk Level

IBRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Low

LOW

HIGH

IBRX Analysts Opinion

IBRX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

IBRX Analysts Opinion

IBRX Analysts opinion is positive and also has improved from the past 3 months

IBRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

100%

IBRX Street Sentiment

IBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

IBRX Performance Sentiment

Sentiments overview associated with IBRX events and the stock performance.

100%

0%

Positive

Negative

10 out of 10
events present

0 out of 10
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$1.98

Resistance
Price

$1.98

Current Price Range

$2.36

Show methods +

Linked to IBRX

IQ

Close Price

Change

CRSP

4.37

53.19

-1.45%

CLDI

3.50

1.16

-2.52%

IBRX Latest Analysis +

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment. J&J ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines approvals and partnerships.

Thu Dec 18, 2025

$2.09 | -0.95%

Potential

Is ImmunityBio Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy?. ImmunityBio Inc. (NASDAQ:IBRX) is among the best NASDAQ stocks under $10 to buy. On December 15 Edward Tenthoff an analyst at Piper Sandler maintained a Buy rating on ImmunityBio Inc. (NASDAQ:IBRX) keeping a price target of $5 which suggests an upside potential of 125.23% from the current level. Three days earlier Jefferies lifted the price [….]

Thu Dec 18, 2025

$2.09 | -0.95%

Rating

Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best multibagger penny stocks to buy right now. On December 12 analysts at Jefferies raised the stocks price target to $9 from 8 while reiterating a Buy rating. The price target hike follows the European Medicines Agencys issuance of a conditional marketing authorization for Anktiva the companys flagship [….]

Thu Dec 18, 2025

$2.09 | -0.95%

Activity

Potential

D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation. Fintel reports that on December 16 2025 D. Boral Capital maintained coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. Analyst Price Forecast Suggests 381.67% Upside

Wed Dec 17, 2025

$2.11 | -2.31%

Rating

ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study. ) on Tuesday said treatment with Anktiva plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months in patients with BCG-unresponsive high-grade papillary-only non-muscle .Published in The Journal of Urology’.s current January 2026 print edition the findings also show tolerable safety that was consistent with BCG treatment alone with 3% of grade 3 and no grade 4 or 5 treatment-related

Tue Dec 16, 2025

$2.17 | -2.70%

Earnings

Jefferies raises Immunitybio stock price target to $9 on European regulatory progress.

Fri Dec 12, 2025

$2.36 | +7.76%

Potential

D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation. Fintel reports that on December 11 2025 D. Boral Capital maintained coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. Analyst Price Forecast Suggests 373.99% Upside

Fri Dec 12, 2025

$2.36 | +7.76%

Rating

FAQ About IBRX Stock Insights

What is IBRX current stock price?

What are IBRX stock strengths?

What is IBRX Risk Level?

What is IBRX market cap and volume?

What is IBRX current Stock IQ?

Should I buy IBRX stock right now?

Is IBRX a Strong Buy right now?

What does a 'Strong Buy' rating mean for IBRX?

What does a 'Strong Sell' rating mean for IBRX?

What factors influence IBRX's Stock IQ?

Explore our IBRX Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored IBRX Stock Strategies
Effective Risk Management

FIND US ON

Receive our IBRX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

IBRX

ImmunityBio

Current Price

$1.98

-$0.06 | -2.94%

52W High

$4.27

MKT CAP

$1.95B

52W Low

$1.83

VOL

$10.92M

P/E Ratio

N/A

AVG VOL

$12.99M

RSI

41.10

TREND

Downtrend

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

IBRX Rewards

Upgraded on attractively valued

IBRX Rewards

Investors confidence is positive

Linked to IBRX

Symbol

IQ

Close

Change

CRSP

4.37

53.19

-1.45%

CLDI

3.50

1.16

-2.52%

IBRX Price Performance

$2.2 (-10.00%)

$2.53 (-21.74%)

$2.44 (-18.85%)

$3.04 (-34.87%)

1year

6month

3month

1month

IBRX Analysts Opinion

IBRX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

IBRX Analysts Opinion

IBRX Analysts opinion is positive and also has improved from the past 3 months

IBRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

100%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NA

100%

IBRX Street Sentiment

IBRX Street Sentiment is extremely bullish and have positive views on the near-term outlook

IBRX Risk Level

IBRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Price under $5

High volatilty

Low

LOW

HIGH

IBRX Performance Sentiment

Sentiments overview associated with IBRX events and the stock performance.

100%

0%

Positive

Negative

10 out of 10
events present

0 out of 10
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$1.98

Resistance
Price

$1.98

Current Price Range

$2.36

Show methods +

IBRX Stock IQ

Login to unlock ImmunityBio (IBRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

IBRX Latest Analysis

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment. J&J ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines approvals and partnerships.

Thu Dec 18, 2025

$2.09 | -0.95%

Potential

Is ImmunityBio Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy?. ImmunityBio Inc. (NASDAQ:IBRX) is among the best NASDAQ stocks under $10 to buy. On December 15 Edward Tenthoff an analyst at Piper Sandler maintained a Buy rating on ImmunityBio Inc. (NASDAQ:IBRX) keeping a price target of $5 which suggests an upside potential of 125.23% from the current level. Three days earlier Jefferies lifted the price [….]

Thu Dec 18, 2025

$2.09 | -0.95%

Rating

Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best multibagger penny stocks to buy right now. On December 12 analysts at Jefferies raised the stocks price target to $9 from 8 while reiterating a Buy rating. The price target hike follows the European Medicines Agencys issuance of a conditional marketing authorization for Anktiva the companys flagship [….]

Thu Dec 18, 2025

$2.09 | -0.95%

Activity

Potential

D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation. Fintel reports that on December 16 2025 D. Boral Capital maintained coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. Analyst Price Forecast Suggests 381.67% Upside

Wed Dec 17, 2025

$2.11 | -2.31%

Rating

ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study. ) on Tuesday said treatment with Anktiva plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months in patients with BCG-unresponsive high-grade papillary-only non-muscle .Published in The Journal of Urology’.s current January 2026 print edition the findings also show tolerable safety that was consistent with BCG treatment alone with 3% of grade 3 and no grade 4 or 5 treatment-related

Tue Dec 16, 2025

$2.17 | -2.70%

Earnings

Jefferies raises Immunitybio stock price target to $9 on European regulatory progress.

Fri Dec 12, 2025

$2.36 | +7.76%

Potential

D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation. Fintel reports that on December 11 2025 D. Boral Capital maintained coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. Analyst Price Forecast Suggests 373.99% Upside

Fri Dec 12, 2025

$2.36 | +7.76%

Rating

Discover IBRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IBRX. We're here to help you make informed investment decisions today.

FIND US ON

Receive our IBRX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

IBRX Stock trends

IBRX Stock performance

IBRX Stock analysis

IBRX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IBRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing IBRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

IBRX Stock Analysis & IQ Rating | ImmunityBio

BQ Stock IQ

IBRX Target Price

IBRX Risk Level

IBRX Analysts Opinion

IBRX Street Sentiment

IBRX Performance Sentiment

Technical Price Levels

Explore our IBRX Stock insights

Receive our IBRX Daily Alerts

IBRX Street Sentiment

IBRX Risk Level

Technical Price Levels

Discover IBRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of IBRX. We're here to help you make informed investment decisions today.

Receive our IBRX Daily Alerts

IBRX Alerts